<DOC>
	<DOCNO>NCT00396240</DOCNO>
	<brief_summary>24 week open label study compare treatment either rosuvastatin rosuvastatin plus initiative improve compliance . If subject reach EAS LDL-C treatment goal week 12 , rosuvastatin titrate 10mg 20mg .</brief_summary>
	<brief_title>ORBITAL : Open-Label Primary Care Study : Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Primary hypercholesterolaemia : Statin na√Øve subject ( LDLC level &gt; 3.5 mmol/L ) subject ineffective `` start dose '' lipidlowering therapy ( LDLC level &gt; 3.1 mmol/L ) . CV risk &gt; 20 % , history CHD establish atherosclerotic disease History severe adverse event another HMGCoA reductase inhibitor Secondary hypercholesterolaemia ; Unstable cardiovascular disease ; Uncontrolled diabetes , active liver disease ; Severe hepatic renal impairment ; Treatment cyclosporin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>rosuvastatin</keyword>
	<keyword>hypercholesterolaemia</keyword>
	<keyword>cholesterol</keyword>
	<keyword>LDL-C</keyword>
	<keyword>triglyceride</keyword>
	<keyword>plasma lipid</keyword>
	<keyword>compliance</keyword>
</DOC>